Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Rarbar99 on Aug 20, 2021 8:06pm

Nuance

Nuance Pharma is also in the process of developing/testing this drug in China. Have the board said anything about them in yesterday's meeting? What if the Chinese don't care about these elevated levels and are still proceeding with the testing without delays? 

There's still $80 million dollars on the line from their part, this should be a big focal point of the topic IMO.

Comment by MrMugsy on Aug 20, 2021 8:37pm
Something was said either at the AGM or at Canaccord. It isn't that Nuance "doesn't care" ... sure they care ... as do our other partners. Nuance has tests to do but they are likely what we'd call supplemental. Fact is ... we don't have a lowest possible dose determined yet. That's what we need to find. There's so much to learn about how it affects the liver at ...more  
Comment by Inthepez on Aug 20, 2021 11:12pm
That question was asked in the AGM if nuance would proceed with ph3. Dan said they can’t. ATE is still running show, nuance is flipping the bill.
Comment by WalkOverTheStrt on Aug 22, 2021 4:46pm
Not as much flipping the bill but it's Antobe's job to have the right course for Nusance or any other partner to take. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities